The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.

ABSTRACT:

Purpose

The microbiota is recognized as an important contributor to the efficacy of immunotherapies. The aim of this study is to analyze the role of gut microbiota and related metabolites in the response of chimeric antigen receptor (CAR) T cells for non-Hodgkin lymphoma.

Experimental design

Stool, serum, and clinical data were collected from 84 patients with non-Hodgkin lymphoma from four hospitals before CD19 CAR T-cell treatment. The microbiota was characterized through 16S rRNA gene sequencing, and serum short-chain fatty acids (SCFA) were measured using mass spectrometry. CAR T cells were exposed to butyrate; their in vitro cytotoxicity was determined, and molecular mechanisms were characterized by flow cytometry and RNA sequencing and then assessed in an in vivo model.

SUBMITTER: Garcia-Vicente R 

PROVIDER: S-EPMC12809112 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature